Podocyte Stress Biomarker Shows Marginal Prognostic Value in Diabetic Kidney Disease
Diabetic kidney disease (DKD) stands as a leading cause of end-stage kidney disease worldwide, emphasizing the critical need for prognostic markers. A recent study explores the potential of urinary podocyte stress biomarkers, shedding light on their role in predicting renal events in individuals with DKD. This study was published in the journal BMC Nephrology by Lingfeng Zeng and colleagues.
Understanding the progression of DKD is vital, and recent research suggests that urinary podocyte stress biomarkers could serve as surrogate markers for podocyte injury. This study delves into the prognostic value of these biomarkers, particularly the podocin:nephrin mRNA ratio, in patients with biopsy-proven DKD.
The study involved 118 patients with confirmed DKD through biopsy and 13 non-diabetic controls. Urinary mRNA levels of nephrin, podocin, and aquaporin-2 (AQP2) were quantified. Renal events, including death, dialysis, or a 40% reduction in glomerular filtration rate, were assessed at the 12-month mark.
Key Findings:
The urinary podocin:nephrin mRNA ratio in DKD patients was significantly higher than in the control group (p = 0.0019).
The ratio correlated with the severity of tubulointerstitial fibrosis in DKD patients (r = 0.254, p = 0.006).
Higher urinary podocin:nephrin mRNA ratio was associated with reduced renal event-free survival at 12 months (unadjusted HR, 1.523; 95% CI 1.157–2.006; p = 0.003).
After adjustments for clinical and pathological factors, the ratio exhibited a trend in predicting renal event-free survival (adjusted HR, 1.327; 95% CI 0.980–1.797; p = 0.067), though not reaching statistical significance.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.